https://orcid.org/0000-0003-1241-7754
References
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
- Centers for disease control and prevention, General Recommendations on Immunization, Recommendations of the Advisory Committee on Immunization Practices (ACIP), January 28, 2011. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.html
- Dela Cruz CS, Pasnick S, Gross JE, Keller J, Carlos WG, Cao B, Jamil S. Adenovirus infection and outbreaks: what you need to know. Am J Respir Crit Care Med. 2019;199(7):P13–p4. doi:10.1164/rccm.1997P13.
- Jones I, Sputnik RP. V COVID-19 vaccine candidate appears safe and effective. The Lancet. 2021;397(10275):642–43. doi:10.1016/S0140-6736(21)00191-4.
- Almuqrin A, Davidson AD, Williamson MK, Lewis P, Heesom K, Morris S, Gilbert S, Matthews DA. SARS-CoV-2 candidate vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals a normal low range of viral backbone gene expression alongside very high levels of SARS-CoV-2 S glycoprotein expression. Res Square. 2020. [published online Oct 20] (preprint). doi:10.21203/rs.3.rs-94837/v1.
- Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadras O, et al. Predictors of mortality in patients with COVID-19-a systematic review. European journal of integrative medicine. 2020;40:101226.